癌症综合肿瘤学的生物标志物。
Cancer Biomarkers for Integrative Oncology.
机构信息
Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at the National Institutes of Health, 9609 Medical Center Drive, Rm. 4-W438, Rockville, MD, 20850, USA.
Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, 02215, USA.
出版信息
Curr Oncol Rep. 2019 Mar 5;21(4):32. doi: 10.1007/s11912-019-0782-6.
PURPOSE OF REVIEW
There has been an increasing interest in using complementary and alternative medicine (CAM) approaches to treat cancer. It is therefore relevant and timely to determine if CAM biomarkers can be identified and developed to guide cancer diagnosis and treatment. Herein, we review the status of cancer biomarkers in CAM research and treatment to stimulate further research in this area.
RECENT FINDINGS
Studies on promising anti-cancer natural products, such as PHY906, honokiol, bryostatin-1, and sulforaphane have demonstrated the existence of potential cancer biomarker(s). Additional studies are required to further develop and ultimately validate these biomarkers that can predict clinical activity of the anti-cancer natural products used alone or in combination with chemotherapeutic agents. A systematic approach is needed to identify and develop CAM treatment associated biomarkers and to define their role in facilitating clinical decision-making. The expectation is to use these biomarkers in determining potential options for CAM treatment, examining treatment effects and toxicity and/or clinical efficacy in patients with cancer.
目的综述：采用补充和替代医学（CAM）方法治疗癌症的兴趣日益浓厚。因此，确定是否可以识别和开发 CAM 生物标志物来指导癌症的诊断和治疗是相关且及时的。在此，我们综述了 CAM 研究和治疗中癌症生物标志物的现状，以激发该领域的进一步研究。
最新发现：对有前途的抗癌天然产物（如 PHY906、厚朴酚、海鞘素-1 和萝卜硫素）的研究表明，存在潜在的癌症生物标志物。需要进一步研究以进一步开发并最终验证这些生物标志物，这些生物标志物可以预测单独使用或与化疗药物联合使用的抗癌天然产物的临床活性。需要采用系统的方法来识别和开发与 CAM 治疗相关的生物标志物，并确定它们在促进临床决策中的作用。期望在确定 CAM 治疗的潜在选择、检查治疗效果和毒性以及（或）癌症患者的临床疗效时使用这些生物标志物。
Zotero 插件